TheraRadar
Clinical-Stage Companies / Tanabe Pharma America

Tanabe Pharma America

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 4/18/2025

24
Total Trials
7
Phase 3
7
Phase 2
3
Recruiting
194
Score

Pipeline by Phase

Phase 3
7
Phase 2
7
Phase 1
11

Therapeutic Focus

Healthy Volunteer ALS Erythropoietic Protoporphyria (EPP) EPP XLP

Clinical Trials (24)

NCT05005975 Phase 3 RECRUITING

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Started: 8/10/2021

NCT04402489 Phase 3 COMPLETED

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Started: 6/1/2020

NCT04577404 Phase 3 COMPLETED

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Started: 10/29/2020

NCT05151471 Phase 3 TERMINATED

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Started: 1/11/2022

NCT04569084 Phase 3 TERMINATED

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Started: 11/13/2020

NCT04165824 Phase 3 COMPLETED

Safety Study of Oral Edaravone Administered in Subjects With ALS

Started: 11/18/2019

NCT06144840 Phase 3 ACTIVE NOT RECRUITING

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

Started: 12/11/2023

NCT03291067 Phase 2 COMPLETED

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Started: 10/9/2017

NCT03541200 Phase 2 COMPLETED

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Started: 4/18/2018

NCT03520036 Phase 2 COMPLETED

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Started: 7/5/2018

NCT03840993 Phase 2 COMPLETED

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Started: 1/15/2019

NCT04440592 Phase 2 COMPLETED

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Started: 2/5/2021

NCT04683848 Phase 2 COMPLETED

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Started: 8/27/2021

NCT06943521 Phase 1 RECRUITING

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Started: 4/18/2025

NCT03809039 Phase 1 TERMINATED

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

Started: 1/15/2019

NCT03381404 Phase 1 COMPLETED

Mass Balance Study With MT-8554

Started: 12/19/2017

NCT03471130 Phase 1 COMPLETED

Definitive QT Study With MT-8554

Started: 4/23/2018

NCT03503266 Phase 1 COMPLETED

Mass Balance Study With MT-7117

Started: 3/23/2018

NCT04793295 Phase 1 COMPLETED

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

Started: 3/23/2021

NCT04656795 Phase 1 COMPLETED

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Started: 12/2/2020

NCT04116476 Phase 1 COMPLETED

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Started: 8/1/2019

NCT04096950 Phase 1 COMPLETED

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

Started: 4/19/2020

NCT03688022 Phase 1 COMPLETED

Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor

Started: 10/25/2018

NCT05241535 Phase 1 COMPLETED

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Started: 1/12/2022

Drug Candidates

MT-8554 1mg MT-8554 5mg MT-8554 10mg Placebo MT-8554 MT-7117 low dose MT-7117 high dose MT-2990 MT-6345 MT-6345 Placebo
Activity Status: Slowing
Last Trial Started: 4/18/2025
Last Trial Ended: 4/9/2025
Trials (12 months): 0
Completed Trials: 18
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.